cytoplasmic proteasome inhibitors, both had a potent and non-competitive inhibitory effect on these homologous serine carboxypeptidases, although they inhibited CPW and hCath A more effectively than CPY in vitro. Ebelactone B exhibited a mixed non-competitive inhibitory effect and selectivity for CPY. Piperastatin A showed competitive inhibition of CPY and hCath A but had little effect on CPW. In contrast, chymostatin inhibited CPW efficiently, while it had less effect on hCath A and CPY. In cell culture system, lactacystin was the most potent as to inactivation of the intralysosomal recombinant hCath A activity expressed in a genetically engineered fibroblastic cell line with galactosialidosis (hCath A deficiency). These results suggest that the specific inhibitory effects of lactacystin and its derivatives on hCath A might be applicable to elucidate the pathophysiological roles in the human deficieecy. 1, GOTO-PPCA and GS-1-PPCA. Aliquots of the cell extracts were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 12.5% acrylamide gels.
Proteins were subjected to SDS-PAGE after reduction with 25mM mercaptoethanol, and then to immunoblotting with anti-PP32N12 and anti-PP20C12 antibodies as described previously29). Detection of the immunoreactive bands was performed with a chemiluminescence kit and a horseradish peroxidase-conjugated anti-rabbit IgG (CLONETECH, Palo Alto, CA, USA). Biotinylated molecular standards (Bbridge International Inc.) were used as molecular mass standard proteins.
Enzyme Assays fluorometrically with 4-methylumbelliferyl glycosides as substrates30). Cath A activity was measured with Z-Phe-Leu as the substrate at pH 5.6 and 6.5, as previously reported with a slight modification31). The pH of the substrate solution was also adjusted to pH 5.6 or 6.5. Proteasome activity was assayed with Z-Gly-Gly-Leu-AMC as the substrate at pH 7.5 as described previously32 proteasome by 50% (IC50) at pH 5.6, 6.5 and 7.5, respectively. Among these inhibitors, omuralide, the active form of lactacystin, had the most potent effect on each enzyme, and inhibited their activities by more than 90% at hCath A for omuralide was relatively higher than that of 
Modes of Inhibition by Peptidase Inhibitors of hCath A and CPY In Vitro
The modes of action of the inhibitors for hCath A were analyzed by means of a Lineweaver-Burk plot in comparison with those for CPY at pH 5.6 and 6.5. reported that the Cath A-like enzyme in human platelets was separable from proteasomes, and was also inhibited by lactacystin and omuralide32). The results indicated that these inhibitors are not necessarily specific for proteasomes, and suggest that some of the biological effects of these inhibitors may be due to the inhibition of Cath A.
In this study we demonstrated directly that the recombinant human Cath A expressed in human fibroblastic cells could be inactivated by treatment with these inhibitors.
Lactacystin and omuralide showed a non-competitive mode of inhibition of the Cath A activity, suggesting that these substances might inhibit the activity irreversibly. Another inhibitor, PSI, specific for proteasomes27), did not show any inhibitory effect on the Cath A activity (data not shown).
Although the inhibition mechanism for Cath A has not been elucidated in detail, the active form of Lactacystin bind covalently and irreversibly to the active serine.
Another possibility is that these compounds may abolish components than lactacystin, and may be inactivated before transport to lysosomes when added to the culture medium.
Alternatively, lactacystin is considered to be more stable in the culture medium and to be intracellularly activated after it has been incorporated into cells like a pro-drug. It would be interesting to determine whether any specific cell surface receptor molecules for lactacystin are present or not, which are delivered to lysosomes after binding with the substance. Poststatin had little effect on hCath A and CPW in vitro, or on the intracellular Cath A activity when added to the culture system. This peptidic inhibitor has been reported to be specific for prolylendopeptidases26). Therefore, the specificity of the inhibitor was suggested to be relatively low for serine carboxypeptidases.
RUDENKO et al. demonstrated the X-ray crystal structure of the precursor form of hCath A and the structural similarity to CPY and CPW, and the conformations of the conserved amino acid residues in the active sites, including the S-H-D catalytic triad, and carboxylate binding were predicted to be very similar among these carboxypeptidases8). Nevertheless, the specificity and preference of serine carboxypeptidase inhibitors for CPY, CPW and hCath A were shown to be rather different in the present study. The unconserved amino acid residues in the active sites of serine carboxypeptidases were considered to contribute to determination of the specificity and preference of inhibitors as well as peptidic substrates.
As the pathophysiological roles of the Cath A activity in vivo have not been fully elucidated, it is necessary to develop a specific inhibitor for Cath A as a probe. Most of the microbial inhibitors used in this study exhibited inhibitory effects on serine carboxypeptidases, and some of them showed selectivity for hCath A among these enzymes.
However, these compounds have the ability to inhibit other enzymes, including esterases, lipase, proteasome and so on.
On the other hand, PPCA gene knock-out mice have been utilized as a human galactosialidosis model for elucidating the pathogenic mechanism and for developing therapeutic methods33 
